BioNexus Gene Lab Corp Common stock (BGLC) — Cash Flow Quality Index
BioNexus Gene Lab Corp Common stock (BGLC) has a Cash Flow Quality Index of -3.38x as of June 2024. Operating cash flow of $-672.27K is below net income of $199.10K, suggesting accrual-heavy earnings not yet converted to cash. Explore cash flow to debt ratio of BioNexus Gene Lab Corp Common stock to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BioNexus Gene Lab Corp Common stock Cash Flow Quality Index (2018–2021)
Historical Cash Flow Quality Index for BioNexus Gene Lab Corp Common stock across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see BioNexus Gene Lab Corp Common stock operating cash flow efficiency.
Annual Cash Flow Quality Index for BioNexus Gene Lab Corp Common stock (2018–2021)
Year-by-year earnings quality comparison for BioNexus Gene Lab Corp Common stock.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 0.01x | $9.16K | $751.57K | ▼ -97.6% |
| 2020 | 0.51x | $552.68K | $1.09 Million | ▲ +104.9% |
| 2018 | -10.36x | $-274.08K | $26.45K | — |